dc.contributor.author | Trevisani, F | |
dc.contributor.author | Ghidini, M | |
dc.contributor.author | Larcher, A | |
dc.contributor.author | Lampis, A | |
dc.contributor.author | Lote, H | |
dc.contributor.author | Manunta, P | |
dc.contributor.author | Alibrandi, MTS | |
dc.contributor.author | Zagato, L | |
dc.contributor.author | Citterio, L | |
dc.contributor.author | Dell'Antonio, G | |
dc.contributor.author | Carenzi, C | |
dc.contributor.author | Capasso, G | |
dc.contributor.author | Rugge, M | |
dc.contributor.author | Rigotti, P | |
dc.contributor.author | Bertini, R | |
dc.contributor.author | Cascione, L | |
dc.contributor.author | Briganti, A | |
dc.contributor.author | Salonia, A | |
dc.contributor.author | Benigni, F | |
dc.contributor.author | Braconi, C | |
dc.contributor.author | Fassan, M | |
dc.contributor.author | Hahne, JC | |
dc.contributor.author | Montorsi, F | |
dc.contributor.author | Valeri, N | |
dc.date.accessioned | 2017-04-03T09:40:44Z | |
dc.date.issued | 2016-11-01 | |
dc.identifier.citation | British journal of cancer, 2016, 115 (11), pp. 1343 - 1350 | |
dc.identifier.issn | 0007-0920 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/541 | |
dc.identifier.eissn | 1532-1827 | |
dc.identifier.doi | 10.1038/bjc.2016.329 | |
dc.description.abstract | BACKGROUND: A significant proportion of patients undergoing radical nephrectomy (RN) for clear-cell renal cell carcinoma (RCC) develop chronic kidney disease (CKD) within a few years following surgery. Chronic kidney disease has important health, social and economic impact and no predictive biomarkers are currently available. MicroRNAs (miRs) are small non-coding RNAs implicated in several pathological processes. METHODS: Primary objective of our study was to define miRs whose deregulation is predictive of CKD in patients treated with RN. Ribonucleic acid from formalin-fixed paraffin embedded renal parenchyma (cortex and medulla isolated separately) situated >3 cm from the matching RCC was tested for miR expression using nCounter NanoString technology in 71 consecutive patients treated with RN for RCC. Validation was performed by RT-PCR and in situ hybridisation. End point was post-RN CKD measured 12 months post-operatively. Multivariable logistic regression and decision curve analysis were used to test the statistical and clinical impact of predictors of CKD. RESULTS: The overexpression of miR-193b-3p was associated with high risk of developing CKD in patients undergoing RN for RCC and emerged as an independent predictor of CKD. The addition of miR-193b-3p to a predictive model based on clinical variables (including sex and estimated glomerular filtration rate) increased the sensitivity of the predictive model from 81 to 88%. In situ hybridisation showed that miR-193b-3p overexpression was associated with tubule-interstitial inflammation and fibrosis in patients with no clinical or biochemical evidence of pre-RN nephropathy. CONCLUSIONS: miR-193b-3p might represent a useful biomarker to tailor and implement surveillance strategies for patients at high risk of developing CKD following RN. | |
dc.format | Print-Electronic | |
dc.format.extent | 1343 - 1350 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | SPRINGERNATURE | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Humans | |
dc.subject | Carcinoma, Renal Cell | |
dc.subject | Kidney Neoplasms | |
dc.subject | MicroRNAs | |
dc.subject | Glomerular Filtration Rate | |
dc.subject | Nephrectomy | |
dc.subject | Biomarkers, Tumor | |
dc.title | MicroRNA 193b-3p as a predictive biomarker of chronic kidney disease in patients undergoing radical nephrectomy for renal cell carcinoma. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2016-09-22 | |
rioxxterms.versionofrecord | 10.1038/bjc.2016.329 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2016-11 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | British journal of cancer | |
pubs.issue | 11 | |
pubs.notes | No embargo | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Signal Transduction & Molecular Pharmacology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Evolutionary Genomics & Modelling | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Gastrointestinal Cancer Biology and Genomics | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Signal Transduction & Molecular Pharmacology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Evolutionary Genomics & Modelling | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Gastrointestinal Cancer Biology and Genomics | |
pubs.publication-status | Published | |
pubs.volume | 115 | |
pubs.embargo.terms | No embargo | |
icr.researchteam | Signal Transduction & Molecular Pharmacology | |
icr.researchteam | Evolutionary Genomics & Modelling | |
icr.researchteam | Gastrointestinal Cancer Biology and Genomics | |
dc.contributor.icrauthor | Lampis, Andrea | |
dc.contributor.icrauthor | Lote, Hazel | |
dc.contributor.icrauthor | Braconi, Chiara | |
dc.contributor.icrauthor | Hahne, Jens | |
dc.contributor.icrauthor | Valeri, Nicola | |